Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Jon C. Ogg | Sep 29, 2014 at 1:10 PM EDT

Can Repros Therapeutics Shares Still More Than Double?

What do you do when an analyst report comes out that maintains a price target position that implies shares can…

Chris Lange | Sep 29, 2014 at 10:55 AM EDT

Will Analysts Start Following Alimera After Its FDA Approval?

Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema…

Lee Jackson | Sep 29, 2014 at 8:30 AM EDT

3 Likely Biotech Buyout Candidates

A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could…

Chris Lange | Sep 26, 2014 at 3:41 PM EDT

Coherus Files for IPO: Biotech to Biosimilars

Coherus Biosciences Inc. filed an S-1 with the Securities and Exchange Commission for an initial public offering.

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

Lee Jackson | Sep 25, 2014 at 8:35 AM EDT

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams…

Jon C. Ogg | Sep 24, 2014 at 11:20 AM EDT

Analyst Now Sees 75% Upside in Sarepta

Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.

Chris Lange | Sep 23, 2014 at 9:15 AM EDT

DBV Technologies Files for IPO, Sort Of

DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering

Chris Lange | Sep 22, 2014 at 2:10 PM EDT

Exagen Diagnostics Files for IPO

Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public…

Chris Lange | Sep 22, 2014 at 1:40 PM EDT

A First, Chiropractic IPO Filing: The Joint

The Joint Corporation has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public…

Chris Lange | Sep 18, 2014 at 1:55 PM EDT

Canaccord Genuity Doubles Price Target for Medivation

Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.

Chris Lange | Sep 18, 2014 at 11:40 AM EDT

Flexion Therapeutics Stumbles on Clinical Hold

In the after-hours on Wednesday, Flexion Therapeutics made a hard fall on the news of a clinical hold.

Chris Lange | Sep 18, 2014 at 10:15 AM EDT

Analyst Sees Incyte Worth 70% More

Incyte has serious upside potential, but the inherent risk within it may be too much for some investors to bear.

Chris Lange | Sep 17, 2014 at 10:05 AM EDT

Why Endo Wants to Acquire Auxilium So Much

Endo International made an unsolicited buyout offer to Auxilium Pharmaceuticals, right after the latter announced that it had entered into…

Chris Lange | Sep 16, 2014 at 10:00 AM EDT

Is Avanir Pharma Fully Valued After Monday’s Rally?

Avanir Pharmaceuticals posted amazing gains on Monday following the announcement of a successful Phase 1 trial, but is it now…

1 … 280 281 282 283 284 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Can Repros Therapeutics Shares Still More Than Double?

Will Analysts Start Following Alimera After Its FDA Approval?

3 Likely Biotech Buyout Candidates

Coherus Files for IPO: Biotech to Biosimilars

Short Sellers Make Moves in Key Biotech Stocks

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

Analyst Now Sees 75% Upside in Sarepta

DBV Technologies Files for IPO, Sort Of

Exagen Diagnostics Files for IPO

A First, Chiropractic IPO Filing: The Joint

Canaccord Genuity Doubles Price Target for Medivation

Flexion Therapeutics Stumbles on Clinical Hold

Analyst Sees Incyte Worth 70% More

Why Endo Wants to Acquire Auxilium So Much

Is Avanir Pharma Fully Valued After Monday’s Rally?

Delaying Social Security to 70 Costs About $158,000 in Skipped Checks, and Still Beats Any Annuity You Can Buy.

The Hardest Money Problem in Retirement Isn’t Saving $500,000. It’s Turning It Into a Monthly Paycheck.

His $50,000 Annuity Finally Paid Out $250,000. Medicare Counted $200,000 in One Year.

Delaying Social Security to 70 Costs About $158,000 in Skipped Checks, and Still Beats Any Annuity You Can Buy.

The Hardest Money Problem in Retirement Isn't Saving $500,000. It's Turning It Into a Monthly Paycheck.

Delaying Social Security to 70 Costs About $158,000 in Skipped Checks, and Still Beats Any Annuity You Can Buy.

The Hardest Money Problem in Retirement Isn’t Saving $500,000. It’s Turning It Into a Monthly Paycheck.

Health and Healthcare Articles

All Health and Healthcare Articles

Can Repros Therapeutics Shares Still More Than Double?

Will Analysts Start Following Alimera After Its FDA Approval?

3 Likely Biotech Buyout Candidates

Coherus Files for IPO: Biotech to Biosimilars

Short Sellers Make Moves in Key Biotech Stocks

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

Analyst Now Sees 75% Upside in Sarepta

DBV Technologies Files for IPO, Sort Of

Exagen Diagnostics Files for IPO

A First, Chiropractic IPO Filing: The Joint

Canaccord Genuity Doubles Price Target for Medivation

Flexion Therapeutics Stumbles on Clinical Hold

Analyst Sees Incyte Worth 70% More

Why Endo Wants to Acquire Auxilium So Much

Is Avanir Pharma Fully Valued After Monday’s Rally?

Delaying Social Security to 70 Costs About $158,000 in Skipped Checks, and Still Beats Any Annuity You Can Buy.

The Hardest Money Problem in Retirement Isn’t Saving $500,000. It’s Turning It Into a Monthly Paycheck.

His $50,000 Annuity Finally Paid Out $250,000. Medicare Counted $200,000 in One Year.

Featured Reads

Delaying Social Security to 70 Costs About $158,000 in Skipped Checks, and Still Beats Any Annuity You Can Buy.

The Hardest Money Problem in Retirement Isn't Saving $500,000. It's Turning It Into a Monthly Paycheck.